Cochrane · systematic review · CD007938
Gabapentin for chronic neuropathic pain in adults
Wiffen, PJ, Derry, S, Bell, RF, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
12
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 8.3%Low 0 · 0%Moderate 10 · 83.3%High 1 · 8.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyGabapentin compared with placebo for postherpetic neuralgia: efficacy
Population: adults with postherpetic neuralgia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
At least 50% reduction in pain or equivalent Gabapentin vs placebo | no estimate extracted | 7 studies · 2031 participants | Moderate |
IMMPACT definition ‐ any substantial pain benefit Gabapentin vs placebo | no estimate extracted | 8 studies · 2260 participants | Moderate |
Patient Global Impression of Change much or very much improved Gabapentin vs placebo | no estimate extracted | 7 studies · 2013 participants | Moderate |
IMMPACT definition ‐ any at least moderate pain benefit (includes Gong 2008 at 25% pain relief) Gabapentin vs placebo | no estimate extracted | 8 studies · 2260 participants | Moderate |
Gabapentin compared with placebo for peripheral diabetic neuropathy: efficacy
Population: adults with peripheral diabetic neuropathy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
At least 50% pain intensity reduction Gabapentin vs placebo | no estimate extracted | 6 studies · 1331 participants | Moderate |
Any definition of substantial benefit (at least 50% pain intensity reduction or PGIC very much improved) Gabapentin vs placebo | no estimate extracted | 6 studies · 1331 participants | Moderate |
PGIC much or very much improved Gabapentin vs placebo | no estimate extracted | 5 studies · 695 participants | Moderate |
Any definition of moderate benefit (at least 30% pain intensity reduction or PGIC much or very much improved) Gabapentin vs placebo | no estimate extracted | 7 studies · 1439 participants | Moderate |
Gabapentin compared with placebo for neuropathic pain (all conditions pooled): adverse events and withdrawals
Population: adults with neuropathic pain
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Participants experiencing at least one adverse event Gabapentin vs placebo | no estimate extracted | 18 studies · 4279 participants | Moderate |
Adverse event withdrawals Gabapentin vs placebo | no estimate extracted | 22 studies · 4346 participants | High |
Serious adverse events Gabapentin vs placebo | no estimate extracted | 19 studies · 3948 participants | Moderate |
Death Gabapentin vs placebo | no estimate extracted | NR | Very low |
Comparison
Population: adults with postherpetic neuralgia or painful diabetic neuropathy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
At least 50% reduction in pain or equivalent | RR 1.6 [1.3, 1.9] | 6 studies · 1816 participants | Moderate |
IMMPACT definition ‐ any substantial pain benefit | RR 1.7 [1.4, 2] | 7 studies · 2045 participants | Moderate |
Patient Global Impression of Change much or very much improved | RR 1.3 [1.2, 1.5] | 7 studies · 2013 participants | Moderate |
IMMPACT definition ‐ any at least moderate pain benefit | RR 1.6 [1.4, 1.8] | 7 studies · 2045 participants | Moderate |
Adverse event withdrawals | RR 1.4 [1.1, 1.7] | 22 studies · 4448 participants | High |
Serious adverse events | RR 1.2 [0.83, 1.7] | 19 studies · 3952 participants | Moderate |
Death | no estimate extracted | NR | Low |